Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Y-33075 is a selective inhibitor of ROCK derived from Y-27632, and is more potent than Y-27632, with an IC50 of 3.6 nM. 在相同实验条件下,摩尔浓度相同的化合物盐形式与游离态具有相同的生物活性,但盐形式 Y-33075 dihydrochloride 的水溶性和稳定性通常比游离态更好。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 858 | 5日内发货 | ||
25 mg | ¥ 5,890 | 6-8周 | ||
50 mg | ¥ 7,660 | 6-8周 | ||
100 mg | ¥ 11,800 | 6-8周 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,330 | 5日内发货 |
Y-33075 的其他形式现货产品:
产品描述 | Y-33075 is a selective inhibitor of ROCK derived from Y-27632, and is more potent than Y-27632, with an IC50 of 3.6 nM. |
靶点活性 | PKC:420 nM, ROCK:3.6 nM, CaMK II:810 nM |
体外活性 | Y-33075 (Y-39983) is a potent inhibitor of ROCK(IC50 of 3.6 nM). Y-33075 also inhibits PKC and CaMKII more potently than Y-27632(IC50s of Y-27632 and Y-33075 for PKC are 9.0 μM and 0.42 μM, respectively), whereas the IC50s of Y-27632 and Y-33075 for CaMKII are 26 μM and 0.81 μM, respectively. The IC50s of Y-27632 and Y-33075 for PKC is 82 and 117 times those for ROCK, respectively, whereas the IC50s of Y-27632 and Y-33075 for CaMKII is 236 and 225 times those for ROCK, respectively[1]. Y-33075 (Y-39983, 10 μM) extends neurites in the retinal ganglion cells (RGCs) compared with those in RGCs treated without Y-39983[2]. Y-33075 (Y-39983, 1 μM) inhibits the contraction of rabbit ciliary artery segments evoked by histamine in Ca2+-free solutions[3]. |
体内活性 | Y-39983 (≥0.01%) significantly lowers intraocular pressure (IOP) at 2 hours after topical administration in rabbits. Y-39983 (0.05%)-treated eyes show significant reduction of IOP between 2 and 7 hours after topical administration in monkeys[1]. Y-39983 (100 μM) increases the regenerating axons of retinal ganglion cells (RGCs) in the eyes of the rats[2]. |
别名 | Y 39983 |
分子量 | 280.32 |
分子式 | C16H16N4O |
CAS No. | 199433-58-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (178.37 mM), sonification/heating is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.5674 mL | 17.8368 mL | 35.6735 mL | 89.1838 mL |
5 mM | 0.7135 mL | 3.5674 mL | 7.1347 mL | 17.8368 mL | |
10 mM | 0.3567 mL | 1.7837 mL | 3.5674 mL | 8.9184 mL | |
20 mM | 0.1784 mL | 0.8918 mL | 1.7837 mL | 4.4592 mL | |
50 mM | 0.0713 mL | 0.3567 mL | 0.7135 mL | 1.7837 mL | |
100 mM | 0.0357 mL | 0.1784 mL | 0.3567 mL | 0.8918 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Y-33075 199433-58-4 Chromatin/Epigenetic Cytoskeletal Signaling PKC Y 39983 Y33075 Y-39983 Y39983 Y 33075 Inhibitor inhibitor inhibit